Economic recovery amid supply chain disruptionsThe Toronto Maple Leafs avoided a disastrous start to their game against Chicago on Monday as a lineup error could have cost the team. Normally, lineup announcements go off without a hitch. Sometimes the PA system has trouble relaying signals, or a name is mispronounced. However it's fairly rare you see a completely different player being introduced. That's what happened with Toronto against Chicago on Monday as it was announced Auston Matthews was to line up first; oddly with Nick Robertson and Steven Lorentz. Toronto avoided disaster as Matthews lined up, but they could have started the game off on the wrong foot. It was a bizarre start to an eventual 4-1 Toronto victory, but it's definitely one of the rarities in hockey. It also showed Matthews' awareness of the intricacies of the league, noting that something similar happened previously and didn't want to risk anything: It also shows great maturity for the Leafs captain to step in briefly in order to help Toronto avoid a rough start. Matthews did his best to help on the scoresheet too, adding a goal in the first to get Toronto on the board. Head coach Craig Berube was none too pleased with the error, blaming the technology messing up nearly costing the team: Matthews made his return Saturday against Tampa Bay and had two assists in the 5-3 victory. There weren't any lineup mishaps that game thankfully, as Toronto is slowly building up momentum to try and lock down the Atlantic Division. Toronto did well in Matthews' absence going 7-2-0 during that span while getting key contributions from John Tavares, Mitch Marner, William Nylander and Bobby McMann. They're doing alright with his return too, going 2-0-0 outscoring their opponents 9-4. With his goal against Chicago, Matthews brings his season point total to 14 points in 15 games (6G, 8A) and has started to show signs of his former self, and not the one hampered by an injury. It's a huge step forward for the Maple Leafs as they head towards a hopefully long playoff run. FAQ: Maple Leafs Avoid Disaster Thanks To Auston Matthews Q1: How did Auston Matthews help Toronto avoid disaster? A1: Toronto avoided disaster because of Auston Matthews lining up to start even though he was not scheduled to due to an error, therefore he played on a different line to save a penalty. Q2: Why did Auston Matthews start if he wasn't scheduled? A2: A technological glitch with the lineup submission led to Matthews' name being called as opposed to Fraser Minten, leading to the confusion and potential penalty for Toronto. In closing, Toronto avoided a rough start to their game against the Blackhawks thanks to the quick thinking and leadership of Auston Matthews. While it wasn't his typical line, he had no problem skating with a different pair so long as it helps Toronto in the end. This article first appeared on Hockey Patrol and was syndicated with permission.
The Darnold-Jefferson connection is thriving for the surging VikingsSalt Lake City, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intermountain Health has named Ryan Smith as its next chief digital and information officer (CDIO), following an extensive national search. He will begin his new role in early 2025. Intermountain’s search for a CDIO included a thorough recruiting process that involved internal and external partners who vetted candidates throughout the United States. Smith is a seasoned leader with deep roots in healthcare technology and an impressive portfolio of experience with Intermountain. He served in several senior leadership roles across the enterprise for nearly 20 years. He then held executive roles with Health Catalyst and served as senior vice president of technology and chief information officer at Banner Health. Following those positions, Smith returned to Intermountain as chief information officer (CIO) from 2020 to 2022 before joining Graphite Health as its chief operating officer. Ryan now serves as Graphite’s interim president and chief executive officer, advancing the nonprofit organization’s endeavor to make healthcare data more universal, accessible, and scalable. “This opportunity is deeply meaningful to me,” said Smith. “I'm excited for the opportunity to make healthcare an easier, safer experience for patients, members, and caregivers alike.” “I’m confident that Ryan is the right leader to help Intermountain successfully navigate both opportunities and obstacles as a model health system in the complex world of healthcare that lies ahead,” said Rob Allen Intermountain Health president and CEO. “He will lead DTS to support our mission, vision, and strategy to simplify, expand proactive care, and improve the healthcare experience for our caregivers, patients, members, and communities.” As Intermountain’s CDIO, Ryan will report directly to Dan Liljenquist, chief strategy officer. He will also serve as a member of the Enterprise Leadership Team. Smith will lead Intermountain's Digital Technology Services (DTS), including DTS Operations, Digital Services, Data Services, Clinical Informatics, Information Security, and Information Technology. Leaders of each team will report directly to Smith and will continue to serve on the DTS Leadership Team. ### Attachment Ryan Smith Lance Madigan Intermountain Health 385.275.8245 intermountainnews@imail.orgHorizon Kinetics CEO Murray Stahl buys $546 in common stock
CRMC's 29th annual Tree of Remembrance brings comfort, support this DecemberSurgical Site Infections Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight 12-23-2024 11:44 PM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Discover Key Insights into the Surgical Site Infections Market with DelveInsight's In-Depth Report @ Surgical Site Infections Market Size [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from the Surgical Site Infections Market Report * The Surgical Site Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034) * According to findings, surgical site infection occur in 2% to 4% of all patients undergoing inpatient surgical procedures. * Findings show that the overall incidence of surgical site infections was approximately 10% in the early 2000s, decreased to 7% by 2007, and further declined to 5% by 2020. * The leading Surgical Site Infections Companies such as MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others * Promising Surgical Site Infections Therapies such as Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard , and others Navigate the complexities of the Surgical Site Infections Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Surgical Site Infections Market Forecast. Click here to get more insights @ Surgical Site Infections Treatment Market [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Surgical Site Infections Epidemiology Segmentation in the 7MM * Total Prevalence of Surgical Site Infections * Prevalent Cases of Surgical Site Infections by severity * Gender-specific Prevalence of Surgical Site Infections * Diagnosed Cases of Episodic and Chronic Surgical Site Infections Download the report to understand which factors are driving Surgical Site Infections epidemiology trends @ Surgical Site Infections Prevalence [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Surgical Site Infections Emerging Drugs * D-PLEX100: PolyPid D-PLEX is a new formulation of extended release of Doxycycline. D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable. The company is conducting a Phase III, prospective, multinational, multicenter, randomized, controlled, two-arm, double blind study to assess efficacy and safety of D-PLEX administered concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incisional infection. * XF-73 Nasal gel: Destiny Pharma XF-73 Nasal gel, a dicationic porphyrin derivative, possesses strong bactericidal properties through a unique mechanism of action. It is a newly developed compound aimed at preventing Staphylococcal infections following surgical procedures. XF-73 Nasal gel is fast acting, requires very few applications and it has a very low propensity to develop bacterial resistance. Thus, XF-73 Nasal gel, preventing post-surgical infections, has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. In April 2024, Destiny Pharma disclosed audited results for 2023, announcing a strategic review to advance XF-73 nasal through Phase III trials. They also re-evaluated trial costs, developing a cost-effective design, and enhanced market understanding for partnerships. Surgical Site Infection Market Outlook The market for surgical site infection treatments is anticipated to grow significantly, driven by key players like PolyPid and Destiny Pharma, who are advancing their lead candidates through various clinical stages. PolyPid's D-PLEX100 and Destiny Pharma's XF-73, among other innovative therapies, aim to provide targeted and effective solutions for preventing and treating surgical site infection. The rising prevalence of surgical site infection, the increasing number of surgical procedures, and enhanced diagnostic technologies underscore the urgent need for advanced treatments. Get In-Depth Knowledge on Surgical Site Infections Market Trends and Forecasts with DelveInsight @ Surgical Site Infections Treatment Market [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Surgical Site Infections Therapies and Companies * Ciprodiazole: MinaPharm Pharmaceuticals * DFA-02 Antibiotic Gel: Duke Clinical Research Institute * ZuraPrep: Zurex Pharma, Inc. * Ertapenem: Merck Sharp & Dohme LLC * XF-73: Destiny Pharma Plc * D-PLEX: PolyPid Ltd. * cefuroxime: GlaxoSmithKline * Dalbavancin: Durata Therapeutics * daptomycin: Cubist Pharmaceutical * ZuraGard: Zurex Pharma, Inc. Surgical Site Infections Treatment Market Treatment for surgical site infections (SSIs) typically involves antibiotics tailored to the specific pathogens identified through wound cultures. The choice of antibiotics is crucial for effectively targeting the infection and reducing resistance. In some cases, if the infection does not respond to antibiotic therapy or if it involves deeper tissues or foreign materials, additional surgical intervention may be required to remove infected tissue, drain abscesses, or address complications. Prompt and appropriate management is essential to prevent the spread of infection, reduce recovery time, and minimize the risk of long-term complications. Gain a strategic edge in the Surgical Site Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Surgical Site Infections Market Forecast. Click here to lead in advancements @ Surgical Site Infections Clinical Trials Assessment [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Scope of the Surgical Site Infections Market Report * Study Period: 2020-2034 * Coverage: 7MM * Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others * Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others * Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies * Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers * Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies * Surgical Site Infections Unmet Needs, KOL's views, Analyst's views, Surgical Site Infections Market Access and Reimbursement Table of Contents 1. Surgical Site Infections Market Report Introduction 2. Executive Summary for Surgical Site Infections 3. SWOT analysis of Surgical Site Infections 4. Surgical Site Infections Patient Share (%) Overview at a Glance 5. Surgical Site Infections Market Overview at a Glance 6. Surgical Site Infections Disease Background and Overview 7. Surgical Site Infections Epidemiology and Patient Population 8. Country-Specific Patient Population of Surgical Site Infections 9. Surgical Site Infections Current Treatment and Medical Practices 10. Surgical Site Infections Unmet Needs 11. Surgical Site Infections Emerging Therapies 12. Surgical Site Infections Market Outlook 13. Country-Wise Surgical Site Infections Market Analysis (2020-2034) 14. Surgical Site Infections Market Access and Reimbursement of Therapies 15. Surgical Site Infections Market Drivers 16. Surgical Site Infections Market Barriers 17. Surgical Site Infections Appendix 18. Surgical Site Infections Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=surgical-site-infections-therapeutics-market-size-in-the-7mm-is-expected-to-increase-by-2034-estimates-delveinsight ] Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage This release was published on openPR.By MARY CLARE JALONICK and MATT BROWN WASHINGTON (AP) — Pete Hegseth, President-elect Donald Trump’s nominee to lead the Defense Department, said he had a “wonderful conversation” with Maine Sen. Susan Collins on Wednesday as he pushed to win enough votes for confirmation. He said he will not back down after allegations of excessive drinking and sexual misconduct. Related Articles National Politics | Donald Trump will ring the New York Stock Exchange bell. It’ll be a first for him National Politics | The Trump and Biden teams insist they’re working hand in glove on foreign crises National Politics | ‘You don’t know what’s next.’ International students scramble ahead of Trump inauguration National Politics | Blinken faces GOP critics in Congress who say Afghanistan withdrawal ‘lit the world on fire’ National Politics | Only about 2 in 10 Americans approve of Biden’s pardon of his son Hunter, an AP-NORC poll finds Collins said after the hourlong meeting that she questioned Hegseth about the allegations amid reports of drinking and the revelation that he made a settlement payment after being accused of a sexual assault that he denies. She said she had a “good, substantive” discussion with Hegseth and “covered a wide range of topics,” including sexual assault in the military, Ukraine and NATO. But she said she would wait until a hearing, and notably a background check, to make a decision. “I asked virtually every question under the sun,” Collins told reporters as she left her office after the meeting. “I pressed him both on his position on military issues as well as the allegations against him, so I don’t think there was anything that we did not cover.” The meeting with Collins was closely watched as she is seen as more likely than most of her Republican Senate colleagues to vote against some of Trump’s Cabinet picks. She and Alaska Sen. Lisa Murkowski, a fellow moderate Republican, did not shy from opposing Trump in his first term when they wanted to do so and sometimes supported President Joe Biden’s nominees for the judicial and executive branches. And Hegseth, an infantry combat veteran and former “Fox & Friends” weekend host, is working to gain as many votes as he can as some senators have expressed concerns about his personal history and lack of management experience. “I’m certainly not going to assume anything about where the senator stands,” Hegseth said as he left Collins’ office. “This is a process that we respect and appreciate. And we hope, in time, overall, when we get through that committee and to the floor that we can earn her support.” Hegseth met with Murkowski on Tuesday. He has also been meeting repeatedly with Iowa Sen. Joni Ernst, a military veteran who has said she is a survivor of sexual assault and has spent time in the Senate working on improving how attacks are reported and prosecuted within the ranks. On Monday, Ernst said after a meeting with him that he had committed to selecting a senior official to prioritize those goals. Republicans will have a 53-49 majority next year, meaning Trump cannot lose more than three votes on any of his nominees. It is so far unclear whether Hegseth will have enough support, but Trump has stepped up his pressure on senators in the last week. “Pete is a WINNER, and there is nothing that can be done to change that!!!” Trump posted on his social media platform last week.
RALEIGH, N.C. (AP) — Aziaha James had 21 points, eight rebounds and five assists, Devyn Quigley scored a career-high 20 points and made four 3-pointers and NC State beat Coastal Carolina 89-68 on Thursday. NC State had its lead trimmed to 54-46 midway through the third quarter before James scored five straight points to begin a 13-2 run that ended in a 19-point lead. Quigley took over in the fourth, making three 3-pointers and scoring 15 points. Coastal Carolina missed 11 of 13 shots spanning the third-quarter break as NC State pulled away. Madison Hayes added 18 points on 7-of-10 shooting for NC State (3-2). James has scored 20-plus in three straight games. The Wolfpack shot 50% from the field, including 11 of 29 from 3-point range. Hayes made her third 3-pointer with 1:12 left in the first half to give NC State a 47-32 lead. Coastal Carolina's Savannah Brooks just beat the halftime buzzer with a basket to give her 17 points and pull within 47-36. Brooks scored 14 of Coastal Carolina’s opening 26 points and she finished the game with 25. Alancia Ramsey added 13 points for Coastal Carolina (4-1), which was picked to finish ninth in the Sun Belt Conference. The Wolfpack travel to the Bahamas to play in the Pink Flamingo Championship against Southern on Monday. Coastal Carolina battles Division II Coker on Wednesday. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP women’s college basketball: https://apnews.com/hub/ap-top-25-womens-college-basketball-poll and https://apnews.com/hub/womens-college-basketballThe field of artificial intelligence (AI) isn't just some fad Wall Street is currently obsessed with but will fade into utter insignificance soon. While some of the hype will die down eventually, the technology has the potential to make corporations more efficient and increase profits over the long run. So, investing in excellent AI companies remains a great idea. In that spirit, let's consider one AI stock that looks like an excellent investment opportunity for 2025 and beyond: Meta Platforms ( META 2.50% ) . Meta Platforms' AI angle Some companies are offering various AI-related services to corporations or consumers. Others are taking on AI-based initiatives to improve their businesses. Many, like Meta Platforms, are doing both. The company's Meta AI is a platform, available for free, that is looking to rival ChatGPT on a range of performance metrics. This AI assistant can perform tasks, from basic search queries to image generation, all for the price of a Facebook or Instagram account -- something many people already have. Besides the generative capabilities of Meta AI, Meta Platforms has released various iterations of its open-source large language model , Llama. These may be free for now, but don't think Meta Platforms doesn't plan on monetizing these efforts eventually. Elsewhere, the company has used AI to increase engagement on platforms like Facebook and Instagram through recommendation algorithms. It also helps companies looking to advertise on its websites and apps through AI-based tools that help them quickly create ads. How are all these initiatives working? Pretty well, according to the company. Meta AI had over 500 million monthly active users as of the third quarter. Meta Platforms also reported that AI-powered video-feed recommendations have helped increase the time people spend on Facebook by 8% and on Instagram by 6% this year. Further, companies using Meta's advertising tools have increased conversions by 7%. So, Meta Platforms' AI business is helping improve its financial results. In the third quarter, the company's revenue increased by 19% year over year to $40.6 billion. The company's Q3 earnings per share of $6.03 was up 37% compared to the year-ago period. Meta also ended the quarter with 3.29 billion daily active users (DAUs). Meta Platforms increasing its DAUs may not have anything to do with AI, but when they spend more time on Facebook and Instagram because of AI, that can directly impact the company's revenue. Looking beyond AI AI could be an important long-term tailwind for Meta Platforms, especially as it seeks to find more ways to monetize some of its current initiatives in the field. It's not a race. Meta Platforms acquired WhatsApp in 2014. Its monetization efforts on this platform have been slow. Meta is ramping up things like paid messaging on WhatsApp, but it represents a tiny percentage of its overall revenue. The point, though, is that Meta Platforms has a massive ecosystem. For now, it continues to make strong revenue and earnings from its advertising business. But that could change in the long run. Whether through AI, WhatsApp, e-commerce, or its metaverse ambitions, Meta Platforms will find many other monetization opportunities. Here are two other reasons to invest in the stock. First, Meta Platforms has a strong competitive advantage, particularly from the network effect . For people or businesses who are on Instagram or Facebook, these platforms only get more useful for almost any purpose as more users join. That's why Meta Platforms' ecosystem is second to none in the social media landscape, and it ensures that the company will remain a leader for the foreseeable future. Second, Meta Platforms is now a dividend-paying company. We can't call it a great dividend stock yet, but maybe it will be that in a decade. In the meantime, opting to reinvest the company's payouts will help boost what should already be strong returns in the next decade.
Week 12 TNF: Steelers-Browns Preview, Props & Prediction
NoneInter Milan Coach Declares ‘Reaching Champions League Final Again Is Our Objective’ After Win Vs RB Leipzig
Canadian National Railway Co. stock falls Wednesday, underperforms market
Millions of university graduates and students will soon wake up to an early Christmas present after the government wiped thousands of dollars off their debts. or signup to continue reading Laws to cap the indexation rate for the Higher Education Loan Program at either the rate of inflation or the wage price index - whichever is lowest - passed federal parliament late Tuesday night after Australians were stung with a 7.1 per cent increase to their student debts in 2023 because of surging inflation. The indexation changes will lead to $3 billion in debt being cleared over coming weeks. "University is a lot more expensive today than when I was at university," Education Minister Jason Clare told reporters in Canberra on Wednesday. "Wiping $3 billion in debt will fix that spike in inflation that happened last year and it'll make sure that never happens again." People with an average HELP debt level will get a $1200 reduction on their loans. Those with a debt of $45,000 will get a decrease of about $2000, while students with $60,000 owning will have debt lowered by $2700. The changes were recommended in the university accords, a review of the tertiary education sector handed down in February. The laws mean university students completing placement will receive payments to help with living costs from July 2025. Students in degrees including teaching, nursing, midwifery and social work will receive an allowance of $319 per week. The reforms were a big win for students and graduates at a time when many Australians were struggling with the high cost of living, Universities Australia chief executive Luke Sheehy said. Though universities have celebrated these measures, other government proposals for the sector have been widely spurned. Labor has attempted to implement a cap on the number of foreign student arrivals from 2025. The reform would be used in place of an immigration rule known as ministerial direction 107, that has throttled student visas. Swinburne University of Technology vice-chancellor Pascale Quester has urged the government to replace the ministerial direction and prioritise visa processing for enrolments in science, technology, engineering and mathematics courses - collectively known as STEM subjects. The number of domestic students taking these courses has dropped steadily, while international student interest has increased by 39 per cent since 2021. "Forget a brain drain, we are at risk of a brain drought," Professor Quester said. "There is so much STEM talent in the region, but we have slammed the door in their faces with hastily-crafted policy." The government is also expected to slash a further 20 per cent off Australians' student debt if it wins the federal election in 2025. Advertisement Sign up for our newsletter to stay up to date. We care about the protection of your data. Read our . Advertisement
NoneNone
Industry Experts Talk About Improving Clinical Quality At The 5Th Risk-Based Quality Management DGE ConferenceReport: Leadership needed to address quantum threat mitigationBy MARY CLARE JALONICK and MATT BROWN WASHINGTON (AP) — Pete Hegseth, President-elect Donald Trump’s nominee to lead the Defense Department, said he had a “wonderful conversation” with Maine Sen. Susan Collins on Wednesday as he pushed to win enough votes for confirmation. He said he will not back down after allegations of excessive drinking and sexual misconduct. Related Articles National Politics | Donald Trump will ring the New York Stock Exchange bell. It’ll be a first for him National Politics | FBI director Christopher Wray will quit before Donald Trump takes office National Politics | Anthony Weiner, ex-congressman jailed in sexting scandal, files to run for NYC City Council seat National Politics | The Trump and Biden teams insist they’re working hand in glove on foreign crises National Politics | Ex-prosecutor charged with meddling in Ahmaud Arbery case appears in court ahead of trial Collins said after the hourlong meeting that she questioned Hegseth about the allegations amid reports of drinking and the revelation that he made a settlement payment after being accused of a sexual assault that he denies. She said she had a “good, substantive” discussion with Hegseth and “covered a wide range of topics,” including sexual assault in the military, Ukraine and NATO. But she said she would wait until a hearing, and notably a background check, to make a decision. “I asked virtually every question under the sun,” Collins told reporters as she left her office after the meeting. “I pressed him both on his position on military issues as well as the allegations against him, so I don’t think there was anything that we did not cover.” The meeting with Collins was closely watched as she is seen as more likely than most of her Republican Senate colleagues to vote against some of Trump’s Cabinet picks. She and Alaska Sen. Lisa Murkowski, a fellow moderate Republican, did not shy from opposing Trump in his first term when they wanted to do so and sometimes supported President Joe Biden’s nominees for the judicial and executive branches. And Hegseth, an infantry combat veteran and former “Fox & Friends” weekend host, is working to gain as many votes as he can as some senators have expressed concerns about his personal history and lack of management experience. “I’m certainly not going to assume anything about where the senator stands,” Hegseth said as he left Collins’ office. “This is a process that we respect and appreciate. And we hope, in time, overall, when we get through that committee and to the floor that we can earn her support.” Hegseth met with Murkowski on Tuesday. He has also been meeting repeatedly with Iowa Sen. Joni Ernst, a military veteran who has said she is a survivor of sexual assault and has spent time in the Senate working on improving how attacks are reported and prosecuted within the ranks. On Monday, Ernst said after a meeting with him that he had committed to selecting a senior official to prioritize those goals. Republicans will have a 53-49 majority next year, meaning Trump cannot lose more than three votes on any of his nominees. It is so far unclear whether Hegseth will have enough support, but Trump has stepped up his pressure on senators in the last week. “Pete is a WINNER, and there is nothing that can be done to change that!!!” Trump posted on his social media platform last week.
Trump's tariffs would devastate auto sector, raise consumer costs: industry leaders